EVALUATED IN HEAVILY
Efficacy population was drawn from 2 pivotal clinical trials
Chronic and accelerated phase adult patients (N=111) evaluated for efficacy were derived from a combined cohort of 2 clinical trials: CML-202 (patients with CML who failed prior imatinib therapy) and CML-203 (patients with CML who failed TKI therapy)1
Patients studied had resistance or intolerance to 2 or more TKIs in addition to prior CML treatments
*TKI therapy includes imatinib, nilotinib, and/or dasatinib.
- Chronic phase: MCyR (CCyR or PCyR, up to 35% Ph+ cells)
- Accelerated phase: MaHR (CHR or NEL) and/or MCyR
Abbreviations: MCyR is major cytogenetic response, CCyR is complete cytogenetic response, PCyR is partial cytogenetic response, Ph+ is Philadelphia chromosome positive, MaHR is major hematologic response, CHR is complete hematologic response, NEL is no evidence of leukemia.
See response rates in Chronic Phase CML >